Funding newsPublished July 24, 2026

Immutep Limited Closes $50.0M Series B Round

Recently funded · $50.0M Series bManufacturingAUView source

Get the full Immutep Limited company profile

Access contacts, investors, buying signals & more

Developing novel immunotherapies for cancer and autoimmune disease, Immutep Limited has secured a $50.0M Series b funding round. The late-stage biotechnology company is a pioneer in understanding and advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a mechanism it harnesses to stimulate or suppress the immune response.

Immutep's diversified product portfolio includes eftilagimod alfa, its lead clinical candidate in oncology, and IMP761, the world's first LAG-3 agonist antibody designed for autoimmune diseases. The company is publicly traded on the Australian Securities Exchange and NASDAQ.

Other Australia companies recently funded

View all

Gold Road Resources
Gold Road is a mid-tier Australian gold producer and explorer with a Tier 1 mine and exploration projects across Australia. Gold Road was established in 2005 and listed on the ASX in 2006. From start-up, the Company’s focus was on greenfields exploration until the discovery of the Gruyere gold deposit in 2013. In 2016 Gold Road agreed a 50:50 joint venture on the project with Gold Fields Limited. Following the mine development from 2017 to mid-2019, Gold Road now have a 50% non-operating interest in the world-class long-life gold mine, together with its joint venture partner. Gruyere is one of Australia’s largest and lowest-cost gold mining operations with all ore currently sourced from a single open pit mine, and has a current mine life to 2032. The Gruyere JV (Gruyere and Golden Highway Deposits) hosts Open Pit Mineral Resources of 6.69 million ounces, and Ore Reserves of 4.05 million ounces (100% basis). At 31 December 2022, Gold Road‘s attributable Mineral Resources total 4.79 million ounces and attributable Ore Reserves total 2.02 million ounces . Gold Road have 100% owned exploration projects in the underexplored and highly prospective Yamarna Belt that hosts the Gruyere gold deposit, located approximately 1,200 kilometres north-east of Perth and 200 kilometres east of Laverton in Western Australia’s north-eastern Goldfields. Following the acquisition of DGO Gold in mid-2022 and new exploration tenement applications, Gold Road now has exploration tenements across Western Australia, South Australia and Queensland covering more than 18,000km² Gold Road’s exploration strategy is to deliver new value-adding, economic gold deposits that could be developed as standalone mining operations driving the creation of shareholder value through organic growth.

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#	Company	Round	Amount	Date
1	Shockwave Medical United States	Unknown	$13.1B	1y ago
2	NeuroEM Therapeutics United States	Unknown

Other recent Series b rounds

Companies that recently closed a Series b round.

#	Company	Round	Amount	Date
1	Acrab Singapore	Series b	$100.0M	today
2	Greenhydro Engineering & Consultancy Turkey	Series b	$32.7M	today

Immutep Limited Closes $50.0M Series B Round

Other Australia companies recently funded

Biggest recent Biotechnology rounds

Other recent Series b rounds

Investors

Key decision-makers

Similar recently funded companies